Navigation Links
Cardiovascular Researchers Use MEDIHONEY(TM) on Sternal Infections Following Open-Heart Procedures
Date:5/13/2008

Full Clinical Study Initiated Following Success with 8 Patients

PRINCETON, N.J., May 13 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, today announced that a group of cardiovascular and thoracic surgeons from the University of Wurzburg, Germany, have used MEDIHONEY(TM) dressings to successfully treat 8 patients with deep sternal wound infections (DSWI), a condition that sometimes arises after open-heart surgeries. The dressings were used in combination with V.A.C.(R) Therapy (KCI, San Antonio, Texas), the largest and fastest growing technology in advanced wound care. Based on the successful results of this observational study, the researchers have initiated a prospective, randomized, controlled study on the influence of MEDIHONEY on the treatment of DSWI.

Derma Sciences CEO Ed Quilty stated, "The results from this initial 8-patient study are very encouraging. DSWI adds significant additional hospitalization costs to median sternotomy and coronary artery bypass grafting (CABG) procedures, and also significantly increases mortality rates in these patients. We believe the addition of MEDIHONEY to these expensive procedures will provide clinicians a cost-effective way to improve outcomes. Additionally, the recent increase in CABG procedures, due to efficacy concerns over less invasive forms of surgery and drug-eluting stent procedures, makes this an attractive and growing target market."

Quilty went on to say, "Use of the V.A.C. in post-surgical applications -- including DSWI -- has been steadily increasing. Overall, this product generates over $1 billion in revenues globally, and is the first true blockbuster in the field of wound care. Gaining acceptance as an adjunct to this therapy will add significantly to the global usage of MEDIHONEY."

The study was published in the proceedings of the 5th Annual Joint Meeting of the German, Austrian, and Swiss Societies for Card
'/>"/>

SOURCE Derma Sciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
2. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
3. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
4. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
5. Cardiologists Tackle Next Frontier in Cardiovascular Disease
6. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
7. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
8. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
9. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) ... Blood Glucose Market" report to their offering. ... market insight focuses on the developments in the self-monitoring ... . Reimbursement analysis and the effects of competitive ... than 73 SMBG meters have been performed, based on ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced ... been dosed in a pharmacokinetic and pharmacodynamic study ... for neuropathic pain. Racemic methadone is ... various pain states and substitution therapy in opioid ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... PDEX ) today announced its financial results for the ... Pro-Dex announced that its existing credit agreement with Wells Fargo ... a product development agreement was signed with a new customer, ... product. , Sales for the first quarter ended September 30, ...
... , PARK CITY, Utah, Oct. 29 Researchers at Thomas ... Life Sciences, have published an article in the Journal of ... designed to selectively detect malignant breast tumors [1] ... malignant and expressed the targeted VPAC1 receptors located on the ...
Cached Medicine Technology:PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 2PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 3PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 5PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 6PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 7PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 8PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 9PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 10New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors 2New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors 3
(Date:12/22/2014)... On December 22, 2014, My Positive Perspective ... for an episode to celebrate Christmas. At the beginning ... so important to you that we all appreciate and ... should respect who Jesus was. I think sometimes we ... That means that on Jesus’ birthday we remember that ...
(Date:12/22/2014)... China (PRWEB) December 22, 2014 Physicians ... MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma (NHL), ... , a leading global healthcare consulting firm. MabThera is ... lymphoma (DLBCL), the most common form of NHL. , ... Access and Barriers,” the incidence of NHL in China ...
(Date:12/22/2014)... Florida (PRWEB) December 22, 2014 Give ... holiday season, the gift of health and vitality. , ... offering its three top-selling anti-aging formulas in special Holiday ... free rush delivery. , Each bottle contains cutting-edge, ... areas that don't work as well as we age. ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... NY (PRWEB) December 22, 2014 ... a 2014 Professional Woman of the Year. She is ... As the largest, most recognized networking organization of professional ... profession, the National Association of Professional Women is a ... 300 Local Chapters. , Ms. Kreider is passionate and ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2
... AHA Create a Unified National Acute Coronary Syndromes ... DALLAS, May 1 The American College of,Cardiology ... Heart Association,s Get With The Guidelines(SM),(GWTG)-Coronary Artery Disease ... create a national unified registry for measuring and,improving ...
... in Product Sales Driven by Robust Growth in Clinical ... ... record revenue of $44.8 million for the first quarter,of fiscal 2008, an increase ... was $1.9 million, or $(0.03) per share, on a,GAAP basis; first quarter net ...
... seed and oil company will focus on new business development ... ULTRA low linolenic, trans fat-free products., ... an,agreement with two key venture capital firms, securing $4 million ... soybean,products. Asoyia is the innovator and leader in developing and ...
... and elsewhere report what is believed to be the ... of heart tissue and the subsequent damage leading to ... findings from the Multiethnic Study of Atherosclerosis (MESA), to ... Journal of the American College of Cardiology, appear to ...
... HILL, N.C., May 1 Leading pharmaceutical,companies ... recruitment,is part of the critical path in ... Trial Excellence: The Science and Art of ... techniques,that speed clinical trial investigator recruitment and ...
... PHILADELPHIA May 1, 2008 Shire plc ... company, announced today that it will present key ... (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and ... extended release, at the American Psychiatric Association (APA) ...
Cached Medicine News:Health News:The American College of Cardiology Foundation's NCDR(R) and the American Heart Association's GWTG Join Forces to Fight Heart Attacks 2Health News:The American College of Cardiology Foundation's NCDR(R) and the American Heart Association's GWTG Join Forces to Fight Heart Attacks 3Health News:Cepheid Reports Record Revenue of $44.8 Million 2Health News:Cepheid Reports Record Revenue of $44.8 Million 3Health News:Cepheid Reports Record Revenue of $44.8 Million 4Health News:Cepheid Reports Record Revenue of $44.8 Million 5Health News:Cepheid Reports Record Revenue of $44.8 Million 6Health News:Cepheid Reports Record Revenue of $44.8 Million 7Health News:Cepheid Reports Record Revenue of $44.8 Million 8Health News:Cepheid Reports Record Revenue of $44.8 Million 9Health News:Cepheid Reports Record Revenue of $44.8 Million 10Health News:Asoyia Secures Venture Capital Funding 2Health News:Asoyia Secures Venture Capital Funding 3Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 3Health News:Strategies for Winning Clinical Investigators in a Competitive Marketplace 2Health News:Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting 2
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: